SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06990 SKB BIO-B

Trading 12-23 15:54:31

415.200

+2.200

+0.53%

High427.000	Low400.000	Vol405.08K
Open407.800	D1 Closing413.000	Amplitude6.54%
Mkt Cap96.82B	Tradable Cap67.58B	Total Shares233.19M
T/O169.19M	T/O Rate0.25%	Tradable Shares162.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":415.2,"timestamp":1766476470677,"preClose":413,"halted":0,"volume":405078,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.3336557768133526,"marketStatus":"Trading","change":2.2,"latestTime":"12-23 15:54:31","open":407.8,"high":427,"low":400,"amount":169185734,"amplitude":0.065375,"askPrice":416.6,"askSize":400,"bidPrice":415.2,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-3.5482590987291363,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766477400000},"marketStatusCode":2,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":413,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":0.955308,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2592143939","title":"Should Kelun-Biotech’s MediLink Settlement and 2026 Framework Deals Reshape SEHK:6990’s Operating Playbook?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592143939","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592143939?lang=en_us&edition=fundamental","pubTime":"2025-12-20 17:13","pubTimestamp":1766222028,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical has called an extraordinary general meeting for 31 December 2025 to approve several 2026 framework agreements covering promotional services, auxiliary R&D support, and procurement and sale of equipment and materials, while also settling trade secret and civil litigation disputes with MediLink Therapeutics through a profit- and income-sharing arrangement.\nBy simultaneously formalising future operating relationships and removing legal uncertainty via the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/should-kelun-biotechs-medilink-settlement-and-2026-framework","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/should-kelun-biotechs-medilink-settlement-and-2026-framework","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2591982430","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Enters Settlement Agreement With Medilink Therapeutics (Suzhou), Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982430","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982430?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:23","pubTimestamp":1765891429,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Enters Settlement Agreement With Medilink Therapeutics , OthersDec 16  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:SETTLEMENT AGREEMENT WITH MEDILINK THERAPEUTICS , OTHERSFurther company coverage: 6990.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2591644254","title":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644254","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644254?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:08","pubTimestamp":1765807696,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. will hold an Extraordinary General Meeting on December 31, 2025, at Meeting Room 1, 2/F, K1 Building, Chengdu, Sichuan Province, the PRC. During the meeting, shareholders will consider continuing connected transactions and the proposed adoption of the 2025 Share Incentive Scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL7qyWVh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","BK0239","LU1979443071.USD","06990","LU1064130708.USD","LU1934453819.USD","LU0196878994.USD","BK1161","BK0060","LU2148510915.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"1193714611","title":"SKB BIO-B (06990): Three Products Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1193714611","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193714611?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:06","pubTimestamp":1765803982,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that three of its products have been included in the National Reimbursement Drug List (NRDL) released by the National Healthcare Security Administration and the Ministry...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1135026529","title":"CICC Maintains Outperform Rating on SKB BIO-B (06990) with Target Price of HK$550","url":"https://stock-news.laohu8.com/highlight/detail?id=1135026529","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135026529?lang=en_us&edition=fundamental","pubTime":"2025-12-12 09:30","pubTimestamp":1765503026,"startTime":"0","endTime":"0","summary":"CICC has issued a research report maintaining its Outperform rating on SKB BIO-B (06990), with a target price of HK$550, implying a 33.4% upside from the current share price. The firm kept its 2026...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1139452041","title":"HK Stock Movement | SKB BIO-B (06990) Rises Over 4% as ITGB6 and Another Drug Candidate Set for Phase I/II Monotherapy Trials in Q1 Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1139452041","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139452041?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:28","pubTimestamp":1765420109,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) surged over 4%, reaching HK$427.4 by the time of writing, with a trading volume of HK$18.32 million. The company recently entered a collaboration with Crescent to jointly develop...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2589484388","title":"Is Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Fairly Valued After Its 175% Year-To-Date Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589484388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589484388?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:21","pubTimestamp":1765149691,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has quietly been on a strong run this year, with the stock up around 175% year to date and roughly 150% over the past year.\nSee our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.\nThat kind of year to date share price return, combined with a 1 year total shareholder return of roughly 150 percent, signals that sentiment has swung sharply toward Kelun Biotech as investors price in faster growth and a lower perceived risk...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-sichuan-kelun-biotech-biopharmaceutical-sehk6990-fairly-v","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-sichuan-kelun-biotech-biopharmaceutical-sehk6990-fairly-v","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"1107632191","title":"Shipping Rates Soar 467% as Commodity Supply Routes Disrupted","url":"https://stock-news.laohu8.com/highlight/detail?id=1107632191","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107632191?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:36","pubTimestamp":1764891391,"startTime":"0","endTime":"0","summary":"Shipping rates have surged by 467% as global commodity supply chains face disruptions. On December 3, the Baltic Dry Index (BDI) reached 2,845 points, marking its highest level since December 6,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","000979.SH","02676","06990","161715"],"gpt_icon":0},{"id":"2589399168","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Partners With Crescent Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589399168","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589399168?lang=en_us&edition=fundamental","pubTime":"2025-12-05 01:24","pubTimestamp":1764869080,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Partners With Crescent BiopharmaDec 4  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:PARTNERS WITH CRESCENT BIOPHARMACOMPANY TO RECEIVE $80 MILLION UPFRONT AND UP TO $1.25 BILLION IN MILESTONESFurther company coverage: 6990.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA021:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2588888137","title":"BUZZ-Crescent Biopharma jumps after cancer drug partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888137","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888137?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:24","pubTimestamp":1764851056,"startTime":"0","endTime":"0","summary":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","BK4139","BK7096","BK1161","BK7508","CBIO","LU0196878994.USD","LU1064131003.USD","BK0239","BK7509","IVX.AU","LU1064130708.USD","LU1979443071.USD","LU1934453819.USD","LU2148510915.USD","06990","BK0060"],"gpt_icon":0},{"id":"1107955650","title":"SKB BIO-B (06990) Forms Strategic Partnership with Crescent Biopharma to Co-Develop and Commercialize Oncology Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1107955650","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107955650?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:50","pubTimestamp":1764849025,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that it has established a strategic partnership with Crescent Biopharma, Inc. and its wholly-owned subsidiary Crescent Biopharma Operating Company, LLC (collectively...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0329678170.USD","LU2488822045.USD","LU0737861772.HKD","06990","BK1161","LU0196878994.USD","LU0329678337.USD","BK1583","BK1209","06078"],"gpt_icon":0},{"id":"2588866818","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Company to Receive $80 Mln Upfront and up to $1.25 Bln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2588866818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588866818?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:35","pubTimestamp":1764848119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA021:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2588868458","title":"Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868458","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868458?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847814,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced a strategic partnership with Kelun-Biotech to jointly develop and commercialize novel oncology therapeutics. Under the terms of the collaboration, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture, and commercialize CR-001, a PD-1 x VEGF bispecific antibody, in Greater China, while Crescent has received exclusive rights to develop and commercialize SKB105, an integrin beta-6-directed antibody-drug conjugate , in the United States, Europe, and other markets outside Greater China. The partnership aims to advance both drug candidates as monotherapies and in combination, with both expected to enter Phase 1/2 clinical trials in early 2026. The collaboration is designed to accelerate development and maximize the potential of these therapies for cancer treatment globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4ZhvgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0314104364.USD","CBIO","IE00BKPKM429.USD","BK0239","LU1064131003.USD","LU1934453819.USD","BK4585","BK0060","BK4139","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","06990","IE00BGHQF748.EUR","LU0196878994.USD","LU1064130708.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","002422","LU2148510915.USD","LU1979443071.USD","LU2210149790.SGD","BK4588","BK4112"],"gpt_icon":0},{"id":"2588886556","title":"Crescent Biopharma Inc - Kelun-Biotech Eligible for Milestones up to $1.25 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886556?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","LU1064130708.USD","LU1979443071.USD","CBIO","LU2148510915.USD","BK0060","LU1934453819.USD","LU0196878994.USD","BK1161","BK4139","LU1064131003.USD","06990","002422"],"gpt_icon":0},{"id":"2588886301","title":"Crescent Biopharma Inc - Co to Receive $20 Mln Upfront Payment,Additional Milestones of up to US$30 Mln From Kelun-Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886301?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK0239","LU1064131003.USD","CBIO","LU2148510915.USD","002422","BK0060","LU1979443071.USD","LU1934453819.USD","LU1064130708.USD","BK4139","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2588886300","title":"Crescent Biopharma Inc - Kelun-Biotech to Receive $80 Mln Upfront Payment,Additional Milestones of up to US$1.25 Billion From Crescent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886300?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK0060","CBIO","002422","LU1934453819.USD","LU0196878994.USD","LU1064130708.USD","LU2148510915.USD","06990","LU1979443071.USD","BK0239","BK4139","LU1064131003.USD"],"gpt_icon":0},{"id":"2588885002","title":"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588885002","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588885002?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002422","06990","BK0239","LU0196878994.USD","LU1064130708.USD","BK1161","CBIO","LU1064131003.USD","BK4139","LU2148510915.USD","LU1934453819.USD","BK0060","LU1979443071.USD"],"gpt_icon":0},{"id":"1111664672","title":"Kelun-Biotech (06990) Announces Monthly Return for November 2025 with Unchanged Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1111664672","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111664672?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:16","pubTimestamp":1764839784,"startTime":"0","endTime":"0","summary":"Kelun-Biotech (06990) published its Monthly Return for Equity Issuer for November 2025. The document indicates that the total authorized share capital remains at RMB 233,185,969, with no changes in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"gpt_icon":0},{"id":"2587971557","title":"Sichuan Kelun-Biotech (SEHK:6990): Unpacking Its Valuation After a 170% YTD Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2587971557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587971557?lang=en_us&edition=fundamental","pubTime":"2025-11-30 19:13","pubTimestamp":1764501190,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn attention among Hong Kong biotech stocks lately as investors look to its innovative drug pipeline and partnerships for potential growth opportunities, particularly following recent sector-wide movements.\nSee our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.\nSichuan Kelun-Biotech Biopharmaceutical has experienced remarkable momentum lately, with a year-to-date share price return of over 170%. This signals growing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-unpacking-its-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-unpacking-its-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2586704672","title":"Kelun-Biotech Reports Promising Phase II Results for Sacituzumab Tirumotecan in Advanced Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586704672","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586704672?lang=en_us&edition=fundamental","pubTime":"2025-11-28 12:07","pubTimestamp":1764302841,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the publication of results from a Phase II clinical study evaluating sacituzumab tirumotecan  monotherapy in patients with advanced or metastatic urothelial carcinoma. The results, already published in the Annals of Oncology, are based on cohort 9 of the MK-2870-001/KL264-01 study and assess sac-TMT in patients whose disease progressed following chemotherapy and immune checkpoint inhibitors. Sac-TMT is a TROP2 antibody-drug conjugate that utilizes an irreversible conjugation technology with a novel topoisomerase I inhibitor payload . As of February 17, 2025, 49 participants were treated with sac-TMT. The confirmed objective response rate was 31%, with a disease control rate of 71% and a median progression-free survival of 5.5 months. The safety profile was considered manageable, with the most frequent grade 3 or 4 adverse events being hematologic toxicities and stomatitis. These results support further evaluation of sac-TM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL3sjPmN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK0239","BK0060","LU1064130708.USD","LU1064131003.USD","LU1979443071.USD","LU1934453819.USD","002422","LU2148510915.USD","BK1161","LU0196878994.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0258},{"period":"1month","weight":-0.0319},{"period":"3month","weight":-0.1957},{"period":"6month","weight":0.2568},{"period":"1year","weight":1.3124},{"period":"ytd","weight":1.5291}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0231},{"period":"3month","weight":-0.0137},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3084},{"period":"ytd","weight":0.2862}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.","exchange":"SEHK","name":"SKB BIO-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SKB BIO-B,06990,SKB BIO-B股票,SKB BIO-B股票老虎,SKB BIO-B股票老虎国际,SKB BIO-B行情,SKB BIO-B股票行情,SKB BIO-B股价,SKB BIO-B股市,SKB BIO-B股票价格,SKB BIO-B股票交易,SKB BIO-B股票购买,SKB BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}